Mir Amir Aghdashi1* and Maryam Yahyapour2
1Department of Rheumatology, Urmia University of Medical Sciences, Iran
2Department of Internal Medicine, Urmia University of Medical Sciences, Iran
Introduction: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune rheumatic disease of unknown etiology interceded by auto antibodies and immune complexes that cause systemic cell and organ damages. This study aimed to evaluate the association between Anti-Smith Antibody (anti- SM ab) and clinical manifestations in patients with disseminated systemic lupus erythematosus. Method: In this cross-sectional study, 72 females with SLE included. Activity disease in patients was assessed by using the University of Toronto SLE Disease Activity Index (SLE-DAI). Serum level of anti-SM ab was measured and clinical manifestations were extracted from patient`s medical records. Results: Six out of 72 patients (8.3%) were anti-Sm positive. Among the patients with anti-Sm positive, the majority of clinical manifestations were observed in one or two patients, except for both mucocutaneous involvement and Lupus nephritis that these were positive in four patients (66.7%). There was no significant association between the anti-SM ab and any clinical manifestations. Conclusion: Due to the lower sample size patients with positive anti-Smith, the relationship between anti-Smith and clinical manifestations was not found.
Anti-smith antibody; Clinical manifestations; Systemic lupus erythematosus
Aghdashi MA, Yahyapour M. Association of Anti-Smith Antibody with Clinical Manifestations in Patients with Disseminated Systemic Lupus Erythematosus. Ann Arthritis Clin Rheumatol. 2019; 2(2): 1015.